Literature DB >> 24333725

Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor.

Hyang Sook Seol1, Hyo Jeong Kang, Hyojeong Kang2, Seul-I Lee1, Na Eun Kim1, Tae Im Kim1, Sung Min Chun2, Tae Won Kim3, Chang Sik Yu3, Young-Ah Suh1, Shree Ram Singh4, Suhwan Chang5, Se Jin Jang6.   

Abstract

Cultures of primary tumors are very useful as a personalized screening system for effective therapeutic options. We here describe an effective method of reproducing human primary colon tumors through primary culture and a mouse xenograft model. A total of 199 primary colon tumor cultures were successfully established under optimized conditions to enrich for tumor cells and to expand it for long-term storage in liquid nitrogen. To examine whether these stored cultures retained original tumor properties, fifty primary cultures were xenografted into NOD-SCID mouse. Histological and tumor marker analysis of four representative tumor xenografts revealed that all of the xenograft retained its primary tumor characteristics. Oncomap analysis further showed no change in the major mutations in the xenografts, confirming that our method faithfully reproduced human colon tumors. A drug sensitivity assay revealed that two of the primary cultures were hypersensitive to oxaliplatin rather than 5-FU, which was used in the patients, suggesting it as an effective therapeutic option. We thus present an effective, reproducible preclinical model for testing various personalized therapeutic options in colon cancer patients.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Colon cancer; Drug sensitivity; Oncomap analysis; Patient derived xenograft (PDX); Primary culture

Mesh:

Substances:

Year:  2013        PMID: 24333725      PMCID: PMC7672533          DOI: 10.1016/j.canlet.2013.11.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  37 in total

1.  Feasibility and limits of an orthotopic human colon cancer model in nude mice.

Authors:  Andreas Thalheimer; Bertram Illert; Marco Bueter; Stefan Gattenlohner; Dominik Stehle; Martin Gasser; Arnulf Thiede; Ana-Maria Waaga-Gasser; Detlef Meyer
Journal:  Comp Med       Date:  2006-04       Impact factor: 0.982

Review 2.  Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise.

Authors:  Christopher G Azzoli; Bernard J Park; William Pao; Maureen Zakowski; Mark G Kris
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

3.  Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.

Authors:  Xiaofang Dong; Ketao Jin; Xiaoyan Hu; Fangmin Du; Huanrong Lan; Na Han; Zhaosheng Ma; Bojian Xie; Binbin Cui; Lisong Teng; Feilin Cao
Journal:  Int J Mol Med       Date:  2012-04-10       Impact factor: 4.101

4.  The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.

Authors:  Thomas John; Derek Kohler; Melania Pintilie; Naoki Yanagawa; Nhu-An Pham; Ming Li; Devang Panchal; Frances Hui; Fannong Meng; Frances A Shepherd; Ming-Sound Tsao
Journal:  Clin Cancer Res       Date:  2010-11-16       Impact factor: 12.531

5.  Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.

Authors:  Federica Francescangeli; Michele Patrizii; Michele Signore; Giulia Federici; Simone Di Franco; Alfredo Pagliuca; Marta Baiocchi; Mauro Biffoni; Lucia Ricci Vitiani; Matilde Todaro; Ruggero De Maria; Ann Zeuner
Journal:  Stem Cells       Date:  2012-09       Impact factor: 6.277

6.  RNA biomarkers in colorectal cancer.

Authors:  Stephen A Bustin; Jamie Murphy
Journal:  Methods       Date:  2012-10-16       Impact factor: 3.608

7.  The promise of patient-derived xenografts: the best laid plans of mice and men.

Authors:  Scott Kopetz; Robert Lemos; Garth Powis
Journal:  Clin Cancer Res       Date:  2012-08-21       Impact factor: 12.531

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.

Authors:  Yujun Hao; Chao Wang; Bo Cao; Brett M Hirsch; Jing Song; Sanford D Markowitz; Rob M Ewing; David Sedwick; Lili Liu; Weiping Zheng; Zhenghe Wang
Journal:  Cancer Cell       Date:  2013-05-02       Impact factor: 31.743

10.  Targeted therapies in colorectal cancer-an integrative view by PPPM.

Authors:  Suzanne Hagan; Maria C M Orr; Brendan Doyle
Journal:  EPMA J       Date:  2013-01-28       Impact factor: 6.543

View more
  13 in total

1.  Establishment and characterization of cell lines from chromosomal instable colorectal cancer.

Authors:  Claudia Maletzki; Michael Gock; Martin Randow; Ernst Klar; Maja Huehns; Friedrich Prall; Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

2.  The Establishment of a Fast and Safe Orthotopic Colon Cancer Model Using a Tissue Adhesive Technique.

Authors:  Hong-Tao Hu; Zhe Wang; Myung Ji Kim; Lu-Shang Jiang; Shi-Jun Xu; Jaeyun Jung; Eunji Lee; Jung-Hoon Park; Nader Bakheet; Sung Hwan Yoon; Kun Yung Kim; Ho-Young Song; Suhwan Chang
Journal:  Cancer Res Treat       Date:  2020-12-15       Impact factor: 4.679

3.  Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.

Authors:  Huanzhang Hu; Yinghe Qiu; Minggao Guo; Yao Huang; Lin Fang; Zhangxiao Peng; Weidan Ji; Yang Xu; Shuwen Shen; Yan Yan; Xuandong Huang; Junnian Zheng; Changqing Su
Journal:  Oncotarget       Date:  2015-01-20

4.  Genomic profiling of patient-derived colon cancer xenograft models.

Authors:  Won-Suk Lee; Hye-Youn Kim; Jae Yeon Seok; Ho Hee Jang; Yeon Ho Park; So-Young Kim; Dong Bok Shin; Suntaek Hong
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

Review 5.  Current status and perspectives of patient-derived xenograft models in cancer research.

Authors:  Yunxin Lai; Xinru Wei; Shouheng Lin; Le Qin; Lin Cheng; Peng Li
Journal:  J Hematol Oncol       Date:  2017-05-12       Impact factor: 17.388

6.  Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer.

Authors:  Yekaterina Y Zaytseva; Piotr G Rychahou; Anh-Thu Le; Timothy L Scott; Robert M Flight; Ji Tae Kim; Jennifer Harris; Jinpeng Liu; Chi Wang; Andrew J Morris; Theru A Sivakumaran; Teresa Fan; Hunter Moseley; Tianyan Gao; Eun Y Lee; Heidi L Weiss; Timothy S Heuer; George Kemble; Mark Evers
Journal:  Oncotarget       Date:  2018-05-15

7.  Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib.

Authors:  Sonia M Novo; Stephen R Wedge; Lesley A Stark
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

8.  Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model.

Authors:  Johannes Klose; Stefan Trefz; Tobias Wagner; Luca Steffen; Arsalie Preißendörfer Charrier; Praveen Radhakrishnan; Claudia Volz; Thomas Schmidt; Alexis Ulrich; Sebastian M Dieter; Claudia Ball; Hanno Glimm; Martin Schneider
Journal:  PLoS One       Date:  2019-02-14       Impact factor: 3.240

9.  Integrated Biobanking and Tumor Model Establishment of Human Colorectal Carcinoma Provides Excellent Tools for Preclinical Research.

Authors:  Christina S Mullins; Bianca Micheel; Stephanie Matschos; Matthias Leuchter; Florian Bürtin; Mathias Krohn; Maja Hühns; Ernst Klar; Friedrich Prall; Michael Linnebacher
Journal:  Cancers (Basel)       Date:  2019-10-09       Impact factor: 6.639

Review 10.  Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer.

Authors:  Christine Koulis; Raymond Yap; Rebekah Engel; Thierry Jardé; Simon Wilkins; Gemma Solon; Jeremy D Shapiro; Helen Abud; Paul McMurrick
Journal:  Cancers (Basel)       Date:  2020-03-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.